...
首页> 外文期刊>The journal of clinical psychiatry >Norepinephrine involvement in antidepressant action.
【24h】

Norepinephrine involvement in antidepressant action.

机译:去甲肾上腺素参与抗抑郁作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Because of the introduction and popularity of the selective serotonin reuptake inhibitor (SSRI) antidepressants, much attention was centered on the indolealkylamine 5-hydroxytryptamine, or serotonin. To some extent, this focus on serotonin occurred at the expense of the catecholamine neurotransmitter norepinephrine. Nevertheless, it has been apparent for almost 40 years that selective blockers of norepinephrine reuptake may be antidepressants (e.g., desipramine). This brief review covers the acute pharmacologic effects that may be responsible for the efficacy of currently marketed antidepressants as well as that of reboxetine, a newly developed selective norepinephrine reuptake inhibitor. Also discussed is the fact that the acute pharmacologic profile of selective reuptake inhibitors often predicts effects they produce when given long term. For example, the long-term administration of SSRIs produces certain effects on serotonergic systems, but not noradrenergic ones. By contrast, selective norepinephrine reuptake inhibitors, when given long term, modify certain noradrenergic parameters, but not serotonergic indices. Finally, it is speculated how drugs that enhance central noradrenergic transmission might ameliorate the symptoms of depression.
机译:由于选择性5-羟色胺再摄取抑制剂(SSRI)抗抑郁药的引入和普及,人们对注意力集中在吲哚烷基胺5-羟色胺或5-羟色胺上。在某种程度上,这种对5-羟色胺的关注是以儿茶酚胺神经递质去甲肾上腺素为代价的。然而,将近40年来,明显的选择性去甲肾上腺素再摄取阻滞剂可能是抗抑郁药(例如地昔帕明)。这篇简短的综述涵盖了可能导致当前市售抗抑郁药以及瑞波西汀(一种新开发的选择性去甲肾上腺素再摄取抑制剂)的功效的急性药理作用。还讨论了这样一个事实,即选择性重摄取抑制剂的急性药理学特征通常可以预测长期给予后产生的作用。例如,SSRIs的长期给药会对血清素能系统产生一定的作用,但对去甲肾上腺素能的系统却没有。相比之下,长期给予选择性去甲肾上腺素再摄取抑制剂会改变某些去甲肾上腺素能参数,但不会改变血清素能指数。最后,推测了增强中枢去甲肾上腺素能传递的药物如何改善抑郁症的症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号